The frequency of CD80+Ecad+ and CD155+Ecad+ cancer cells specifically increased in mixed patient cSCCs (Fig. 2j, k), suggesting that the upregulation of these IC ligands is associated with the enrichment of hybrid E/M cancer cells at intermediate cSCC stages. The gene discussed is CD80; the disease is cancer.